## 4 Discussion and Conclusions
\begin{table}
\begin{tabular}{c c c c c c} \hline \hline
**Related Work** & **Imaging, Disease (\# Samples)** & **Dependence** & **Extraction Tool (\# Features)** & **Main Findings** \\ \hline [PERSON] et al. [8] & CT, phantom (8 by SCT scanners) & vowel size, gray levels & in-house tool (213) & In total, 150 features are reproducible across voxel sizes \\ \hline [PERSON] et al. [9] & CT, liver cancer (43) & slice thickness & PyRadomics (107) & In total, 75-90\% of features are highly robust \\ \hline [PERSON] et al. [10] & MRI (DCE-MRI), breast cancer (612) & magnetic field strength & PyRadomics (38) & In total, 5 features are robust across field strength \\ \hline [PERSON] et al. [11] & MR (T2 av)/prostatic cancer/14 & image signal normalization & PyRadomics (91) & In total, 60\% of features have a poor reproducibility \\ \hline [PERSON] et al. [12] & CT, various lesion types (10,000 slices) + validation on NSCLC (77,988 slices) & super-resolution & PyRadomics (75) & In total, 10\% features have excellent robustness \\ \hline [PERSON] et al. [13] & CT, NSCLC C31 (1) + HNSCC (19) & image perturbation & N.A, (4052) & In total, 2310 (57,493) NSCLC are robust, 54 (11,373) features are robust in both cohorts \\ \hline [PERSON] et al. [14] & CT, RCC (89) + CK (93) & image resampling and perturbation & in-house tool (32) & In total, 94\% and 87-9\% of features achieve the best reproducibility in RCC and CK \\ \hline [PERSON] et al. [15] & MRI (PLAIR, T1 av), glioblastoma (89) & segmentation method & PyRadomics (108) & In total, 94\% and 87-9\% of features achieve the best reproducibility in RCC and CK \\ \hline [PERSON] et al. [15] & MRI (PLAIR, T1 av), glioblastoma (89) & segmentation method & PyRadomics (108) & In total, 94\% and 87-9\% of features achieve the best reproducibility in RCC and CK \\ \hline [PERSON] et al. [16] & MR (T1 av), breast cancer (102) & inter-observer segmentation & RandomX (1328) + PyRadomics (83) & In total, 94\% and 87-9\% of features have robust \\ \hline [PERSON] et al. [17] & CTA, culpt lesions in carotid arteries (41) & inter-observer segmentation & PyRadomics (93) & In total, 55\%, 52\% (51,978) of features have excellent robustness, 33,5\% (51,978) of features have moderate robustness \\ \hline \hline \end{tabular}
\begin{tabular}{c c} \hline \hline
**Proposed Work** & MRI (DCE-MRI), breast cancer (111) & quantization level, inter-observer segmentation variability & PyRadomics (49) & In total, 87\% (43) + 9\% of features were robust (CC - 0.9 with binContent - 32, CHC And CLEM features have high robustness, CLEM features have moderate robustness \\ \hline \hline \end{tabular}
\end{table} 
Table 6: Overview of the state-of-the-art results, along with the considered settings, to assess the robustness of radiomic features. **Author Contributions:** Conceptualization, C.M. and L.R. ; methodology, C.M. and L.R. ; software, C.M. ; validation, C.M. and L.R. ; formal analysis, C.M. and L.R. ; investigation, C.M. ; resources, M.D., A.O., and I.D. ; data curation, M.D., A.O., and I.D. ; writing--original draft preparation, C.M. and L.R. ; writing--review and editing, M.D., A.O., V.C., and T.V.B. ; visualization, C.M. and L.R. ; supervision, V.C. and T.V.B. ; project administration, T.V.B. All authors have read and agreed to the published version of the manuscript. **Funding:** This research received no external funding. **Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of \"Azienda Ospedaliera Universitaria Policlinico P.Giaccone\" of Palermo, Italy (protocol code n.1/2020-15/01/2020). **Informed Consent Statement:** Retrospective data collection was approved by the Ethics Committee. The requirement for evidence of informed consent was waived because of the retrospective nature of our study. **Conflicts of Interest:** The authors declare no conflict of interest.